About SynGen
SynGen is a company based in Sacramento (United States) founded in 2009 was acquired by Cesca Therapeutics in July 2017. SynGen has raised $16.81 million across 14 funding rounds from investors including GE Capital, Cesca Therapeutics and Bay City Capital. SynGen operates in a competitive market with competitors including NanoCellect Biomedical, ThinkCyte, Hemotune, Singulex and Cell Microsystems, among others.
- Headquarter Sacramento, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.81 M (USD)
in 14 rounds
-
Latest Funding Round
$500 K (USD), Series A
Apr 21, 2017
-
Investors
GE Capital
& 2 more
-
Employee Count
Not available
-
Acquired by
Cesca Therapeutics
(Jul 07, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SynGen
SynGen has successfully raised a total of $16.81M across 14 strategic funding rounds. The most recent funding activity was a Series A round of $500 thousand completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SynGen
SynGen has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include GE Capital, Cesca Therapeutics and Bay City Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked | |
|
Commercial aircraft and equipment leasing and lending services are provided.
|
Locked | Locked | Locked | |
|
Cell-based therapeutics are developed for regenerative medicine applications.
|
Locked | Locked | Locked |
Investor details for SynGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SynGen
Investment portfolio details for SynGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SynGen
Detailed financials for SynGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syngen Comparisons
Peer comparison for SynGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SynGen
SynGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NanoCellect Biomedical, ThinkCyte, Hemotune, Singulex and Cell Microsystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops flow cytometry and cell sorting technology
|
|
| Locked | Locked | Locked |
Cell analysis and sorting technologies are developed with AI integration.
|
|
| Locked | Locked | Locked |
Developer of a device for blood purification
|
|
| Locked | Locked | Locked |
Single-molecule counting technology is developed for cardiovascular biomarker detection.
|
|
| Locked | Locked | Locked |
Developer of a technology to isolate and recover single cells for molecular analysis
|
|
| Locked | Locked | Locked |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
Detailed competitors of SynGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syngen
Complete news archive for SynGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SynGen
SynGen was founded in 2009 and raised its 1st funding round 3 years after it was founded.
SynGen is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
SynGen is a funded company, having raised a total of $16.81M across 14 funding rounds to date.
SynGen develops cell separation tools and accessories, applying design to aid regenerative medicine workflows. SynGen design and manufacture products that focus on improving recovery of target cells, depletion of contaminating cells, efficiency and operator ease of use. Also, reduces time for the development of therapeutic products.
SynGen's top competitors include NanoCellect Biomedical, ThinkCyte and Silicon Biosystems.
SynGen has 3 investors. Key investors include GE Capital, Cesca Therapeutics, and Bay City Capital.